Understanding how Rho protein affects the virulence of C. difficile bacteria
Rho dependent regulation of Clostridioides difficile virulence
['FUNDING_FELLOWSHIP'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-10825902
This study is looking at how a specific protein called Rho affects the harmful effects of Clostridioides difficile, a germ that can cause serious gut infections, especially after taking antibiotics, with the goal of finding new ways to treat these infections and help patients feel better.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-10825902 on ClinicalTrials.gov |
What this research studies
This research investigates the role of the Rho protein in regulating the virulence of Clostridioides difficile, a bacterium that can cause severe intestinal infections, particularly after antibiotic use. The study aims to understand how Rho influences the expression of toxins that lead to symptoms like diarrhea and colitis. By exploring the genetic mechanisms involved, the research seeks to identify potential targets for new treatments that could mitigate the harmful effects of this pathogen. Patients may benefit from insights that could lead to more effective therapies for C. difficile infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced or are at risk for C. difficile infections, particularly those with a history of antibiotic use.
Not a fit: Patients who do not have C. difficile infections or are not at risk for such infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that reduce the severity of C. difficile infections and improve patient outcomes.
How similar studies have performed: Previous research has shown that targeting bacterial regulatory mechanisms can lead to significant advancements in treating infections, suggesting that this approach may also yield promising results.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PLASKON, DYLAN — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: PLASKON, DYLAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.